Business First Bancshares Azioni (NASDAQ: BFST)

Business First Bancshares (NASDAQ:BFST) Azioni

Business First Bancshares

Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.

Business First Bancshares, Inc. - Common Stock

Business First Bancshares Inc

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $28 price target.

News

Price Target

Reiteration

Analyst Ratings

ACAD

Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $28 Price Target

JP Morgan analyst Hong Zhang initiates coverage on Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) with a Overweight rating and announces Price Target of $31.

Initiation

JP Morgan Initiates Coverage On Weyerhaeuser with Overweight Rating, Announces Price Target of $31

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Niagen Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAGE#NASDAQ">NAGE</a>) with a Buy and maintains $11 price target.

NAGE

HC Wainwright & Co. Reiterates Buy on Niagen Bioscience, Maintains $11 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $70 to $80.

RYTM

HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $80

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) with a Buy and maintains $4 price target.

PHIO

HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $4 Price Target

The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Noble Corporation PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>)</h3>
<ul>
<li>On April 7, Barclays analyst Eddie Kim maintained Noble Corp with an Overweight rating and lowered the price target from $39 to $29. The company's stock fell around 19% over the past five days and has a <a href="https://www.benzinga.com/quote/NE">52-week low of $17.40</a>.</li>
<li>RSI Value: 29.2</li>
<li>NE Price Action: Shares of Noble gained 5.4% to close at $19.41 on Monday.</li>
<li>Edge Stock Ratings: 8.25 Momentum score with Value at 93.03. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/ne"><img loading="lazy" decoding="async" width="412" height="171" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030815/image-28.png" alt="" class="wp-image-861266" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030815/image-28.png 412w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030815/image-28-300x125.png 300w" sizes="(max-width: 412px) 100vw, 412px" /></a></figure>
<h3 class="wp-block-heading">Seadrill Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>)</h3>
<ul>
<li>On March 19, Citigroup analyst Scott Gruber maintained Seadrill with a Buy rating and lowered the price target from $46 to $35. The company's stock fell around 20% over the past month and <a href="https://www.benzinga.com/quote/SDRL">has a 52-week low</a> of $18.25.</li>
<li>RSI Value: 27.3</li>
<li>SDRL Price Action: Shares of Seadrill gained 4.4% to close at $20.08 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408">SDRL stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="930" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030900/image-29.png" alt="" class="wp-image-861268" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030900/image-29.png 930w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030900/image-29-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08030900/image-29-768x691.png 768w" sizes="(max-width: 930px) 100vw, 930px" /></figure>
<h3 class="wp-block-heading">Nabors Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>)</h3>
<ul>
<li>On March 27, Morgan Stanley analyst Daniel Kutz maintained Nabors Industries with an Overweight rating and lowered the price target from $115 to $75. The company's stock fell around 28% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/NBR">low of $26.23.</a></li>
<li>RSI Value: 25.8</li>
<li>NBR Price Action: Shares of Nabors Industries gained 3.1% to close at $29.86 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408">NBR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408"><img loading="lazy" decoding="async" width="867" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08031003/image-30.png" alt="" class="wp-image-861269" style="width:491px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08031003/image-30.png 867w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08031003/image-30-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08031003/image-30-768x736.png 768w" sizes="(max-width: 867px) 100vw, 867px" /></a></figure>
BZ Edge Rankings: Find out where other stocks stand—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">explore the full comparison now</a>.
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a> </li>
<li></li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

SDRL

Top 3 Energy Stocks You'll Regret Missing In Q2

JP Morgan analyst Bryan Smilek downgrades Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) from Neutral to Underweight.

Downgrades

CHGG

JP Morgan Downgrades Chegg to Underweight

Contracts

V2X Awarded $62M Contract To Support COBRA DANE Radar Operational Readiness Through 2027

General

KIDZ

KIDZW

Classover Announces Development Of A Next-Generation Artificial Intelligence Powered Tutoring Platform

JP Morgan analyst Matthew Boss upgrades Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) from Neutral to Overweight and lowers the price target from $19 to $17.

Upgrades

LEVI

JP Morgan Upgrades Levi Strauss to Overweight, Lowers Price Target to $17

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $133 price target.

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

JP Morgan analyst Richard Shane upgrades Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) from Neutral to Overweight and maintains the price target from $60 to $60.

ESNT

JP Morgan Upgrades Essent Group to Overweight, Maintains Price Target to $60

Management

Harley-Davidson's Board Of Directors Confirm On-Going CEO Search Process

As global markets continue to swing wildly in the aftermath of Trump's tariffs coming into play, an old observation from Berkshire Hathaway&#8217;s former vice-chair, <a href="https://www.benzinga.com/25/04/44659224/billionaire-charlie-munger-said-hed-be-the-richest-man-on-earth-if-he-could-go-back-100-years-and-start-over-i-could-have-done-a-lot-better">Charlie Munger,</a><a href="https://www.benzinga.com/25/04/44659224/billionaire-charlie-munger-said-hed-be-the-richest-man-on-earth-if-he-could-go-back-100-years-and-start-over-i-could-have-done-a-lot-better"> sounds more relevant than ever</a>. 
What Happened: During volatility, Munger once told shareholders: "The market is not going to do exactly what you want when you want it&#8230;&#8221;
&#8220;I wouldn&#8217;t worry too much about what happens over six months or twelve months. I don&#8217;t think you&#8217;re really all that welcome in this room if the short-term orientation is what turns you on."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Charlie Munger: &quot;The market is not going to do exactly what you want when you want it &#8230; I wouldn&#39;t worry too much about what happens over six months or twelve months. I don&#39;t think you&#39;re really all that welcome in this room if the short-term orientation is what turns you on.&quot; <a href="https://t.co/yQLY20cK4P">pic.twitter.com/yQLY20cK4P</a>
&mdash; Kevin Carpenter (@kejca) <a href="https://twitter.com/kejca/status/1908919285847556486?ref_src=twsrc%5Etfw">April 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/04/44680547/dave-ramsey-caller-asks-if-they-should-stop-contributing-during-market-collapse-ten-years-from-now-you-wont-even-remember-this-crap">Dave Ramsey Caller Asks If They Should Stop Contributing During Market Collapse — &#8216;Ten Years From Now You Won&#8217;t Even Remember This Crap&#8217;</a>
Why It Matters: Trump's sweeping tariffs have triggered a <a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks">market meltdown, wiping out $9 trillion</a> in just six weeks—an impact rivaling the losses seen during the peak of the COVID-19 crash and surpassing the year-long decline following the 2008 Lehman Brothers collapse, according to Bear Traps Report founder Lawrence McDonald.
On Monday, stocks swung as investors responded to contradictory signals. Hopes that tariffs might be halted for a bit pushed the S&amp;P 500 almost 7% from its recent low, only for the market to change course when the Trump administration confirmed the 25% hike on Chinese goods would go ahead. <a href="https://www.benzinga.com/news/global/25/04/44679330/will-trump-impose-higher-tariffs-on-china-crypto-bettors-now-see-an-80-possibility">China threatened retaliation, leading to a fresh wave of uncertainty</a>. By evening, futures for the Dow, S&amp;P 500, and Nasdaq-100 had each climbed by more than 1%.

The recent episode underscores just how reactive markets have become—bouncing on speculation, then falling on confirmation. <a href="https://www.benzinga.com/markets/25/04/44657195/charlie-munger-slams-teaching-stock-trading-to-young-people-its-like-trying-to-induce-young-people-to-start-off-on-heroin">Munger's lesson highlights the danger of chasing headlines</a> and banking on instant gratification from markets that are, by nature, unpredictable.
At a time when even experienced investors are tempted to time the chaos, <a href="https://www.benzinga.com/personal-finance/25/04/44654791/billionaire-charlie-munger-hated-being-told-what-to-do-he-said-getting-rich-meant-you-could-say-to-hell-with-them-and-avoid-needing-anyone">Munger's reminder</a> stands steady: patience beats panic, particularly when the noise is loudest.
Image via Shutterstock
Read Next: <a href="https://www.benzinga.com/25/04/44681272/jim-cramer-questions-market-strength-amid-chinas-retaliatory-tariffs-oversold-panic-or-a-big-trap">Jim Cramer Cautions Against Jumping In As Oversold Market Sparks Futures Rebound Without Clear Catalyst: &#8216;Is It All A Big Trap?&#8217;</a>

Equities

Charlie Munger Once Said, 'The Market Won't Do Exactly What You Want, When You Want' — As Tariff Jitters And Wild Swings Remind Investors Why Long-Term Thinking Matters

JP Morgan analyst Richard Shane upgrades Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) from Underweight to Neutral and lowers the price target from $12.5 to $12.

GHLD

JP Morgan Upgrades Guild Holdings to Neutral, Lowers Price Target to $12

Health Care

KURA

Kura Oncology Submits New Drug Application (NDA) To The FDA For ziftomenib For The Treatment Of Acute Myeloid Leukemia (AML)

JP Morgan analyst Jimmy Bhullar upgrades RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) from Neutral to Overweight and maintains the price target from $284 to $284.

JP Morgan Upgrades RenaissanceRe Holdings to Overweight, Maintains Price Target to $284

Biotech

Financing

Offerings

IBRX

ImmunityBio Announced Registered Direct Offering Of Approximately $75M In Gross Proceeds With A Single Institutional Investor, If Fully Exercised, The Warrants Could Result In Additional Gross Proceeds Of Up To Approximately $90M

JP Morgan analyst Jimmy Bhullar upgrades Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) from Neutral to Overweight and raises the price target from $115 to $150.

PLMR

JP Morgan Upgrades Palomar Hldgs to Overweight, Raises Price Target to $150

ZENA

ZenaTech Scales Domestic Drone Production For Commercial And Defense Markets Without Raising Prices

Press Releases

Business First Bancshares, Inc. Receives Regulatory Approval of its Merger with Oakwood Bancshares, Inc.

Business First Bancshares, Inc., completes acquisition of Oakwood Bancshares, Inc.

Business First Bancshares, Inc. Announces Third Quarter 2024 Earnings Release Date and Conference Call

b1BANK Chooses Spiral to Promote Financial Wellness and Support Community Impact Through Everyday Banking

b1BANK Promotes Jerry Vascocu to President

Earnings

Business First Bancshares, Inc., Announces Financial Results for Q3 2024

Business First Bancshares, Inc. Announces Fourth Quarter 2024 Earnings Release Date and Conference Call

Dividends

Business First Bancshares, Inc., Announces Financial Results for Fiscal Year 2024 and Q4 2024

b1BANK Announces Senna Bayasgalan as Chief Marketing Officer

Business First Bancshares, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call

Comments

Business First Bancshares

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO